Gasporox (GPX) Q2 2026 earnings summary

Executive summary

• Achieved significant product launches, including the automated LineArch Plus and next-gen GPX3000 for vial inspection, expanding offerings for pharma and food sectors.

• Revenue for Q2 2026 rose to 8,778 KSEK from 6,864 KSEK year-over-year, driven by strong order intake and new market segments.

• Strategic focus on broadening applications and international expansion, with new partnerships and board appointments to support growth.

Financial highlights

• Q2 2026 net sales: 8,778 KSEK (up from 6,864 KSEK in Q2 2025); six-month sales: 17,574 KSEK (up from 10,834 KSEK year-over-year).

• Operating result for Q2: -1,656 KSEK (improved from -3,426 KSEK); six-month operating result: -2,817 KSEK (improved from -7,545 KSEK).

• Cash flow for Q2: -3,369 KSEK (vs. -5,625 KSEK); cash at period end: 9,464 KSEK.

• Result per share Q2: -0,23 SEK (vs. -0,41 SEK); six months: -0,40 SEK (vs. -0,90 SEK).

Outlook and guidance

• Positioned for continued growth with a broadened product portfolio and entry into new market segments.

• Focus on scaling up recurring revenue through service agreements and after-market sales.

• Long-term goal to install solutions in 10-20% of new production lines.